Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1997

View Archived Issues

Pharmacia & Upjohn reports fourth-quarter and full-year sales and earnings

Sepracor announces 1996 financial results

Vanguard Medica preliminary results for the year ended December 31, 1996

Vasogen reports fiscal 1996 results

Antitumor agents disclosed by University of Vermont

HBV mutants for diagnosis and therapy described by Abbott

Procyte discloses zinc(II) complexes especially effective against HIV

Agents for CNS disorders described by American Home Products

Pharmacia & Upjohn discloses aromatase inhibitors

New antifungal agents from Lilly

MMP inhibitors from Ono

Merck KGaA discloses ET antagonists

AY-4166: preclinical toxicity and pharmacokinetics studies

Preclinical toxicity, pharmacokinetics and metabolism of SM-9018 described

New PDE III/IV inhibitor described

Potent, long-acting ETA antagonist described by Zeneca

New selective alpha1a/A-antagonist from Abbott

ImaRx reports discoveries related to gene expression enhancement

AltaRex receives funding for clinical trials on Ovarex

Synsorb sponsors research on carbohydrate synthesis

Axcan signs distribution agreements for Protectaid

Emisphere's carriers for oral delivery of proteins covered by patent

Spiros products progressing through pipeline

Patient enrollment in phase I study of HIV/ACT complete

Pharmacia & Upjohn purchases U.S. manufacturing rights for Cygnus' Nicotrol

Fluticasone + loratadine for seasonal allergic rhinitis

Millennium obesity gene patent application receives U.S. notice of allowance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...